tbuckley/cabot-search huggingface dataset:
Characterization of the osteogenic potential of mesenchymal stem cells from human periodontal ligament based on cell surface markers
Authors: Ruth Alvarez, Hye-Lim Lee, Cun-Yu Wang, Christine Hong
Journal: International Journal of Oral Science (2015)

Mesenchymal stem cell (MSC)-mediated therapy has been shown to be clinically effective in regenerating tissue defects. For improved regenerative therapy, it is critical to isolate homogenous populations of MSCs with high capacity to differentiate into appropriate tissues. The utilization of stem cell surface antigens provides a means to identify MSCs from various tissues. However, few surface markers that consistently isolate highly regenerative MSCs have been validated, making it challenging for routine clinical applications and making it all the more imperative to identify reliable surface markers. In this study, we used three surface marker combinations: CD51/CD140α, CD271, and STRO-1/CD146 for the isolation of homogenous populations of dental mesenchymal stem cells (DMSCs) from heterogeneous periodontal ligament cells (PDLCs). Fluorescence-activated cell sorting analysis revealed that 24% of PDLCs were CD51+/CD140α+, 0.8% were CD271+, and 2.4% were STRO-1+/CD146+. Sorted cell populations were further assessed for their multipotent properties by inducing osteogenic and chondrogenic differentiation. All three subsets of isolated DMSCs exhibited differentiation capacity into osteogenic and chondrogenic lineages but with varying degrees. CD271+ DMSCs demonstrated the greatest osteogenic potential with strong induction of osteogenic markers such as DLX5, RUNX2, and BGLAP. Our study provides evidence that surface marker combinations used in this study are sufficient markers for the isolation of DMSCs from PDLCs. These results provide important insight into using specific surface markers for identifying homogenous populations of DMSCs for their improved utilization in regenerative medicine. Dental stem cells with the greatest potential for regenerating bone and cartilage can be identified by three proteins on the cell surface. Christine Hong and co-workers at the University of California Los Angeles investigated stem cells purified from the ligaments that attach teeth to the jaw bone. This tissue can be readily obtained from extracted teeth. It offers a convenient source of stem cells that have previously been shown to regenerate bone, the surface layer of tooth root, and the ligament itself. Hong's team found that human stem cells obtained in this way vary significantly in their regenerative capacity and therefore therapeutic potential. They identified the combination of surface proteins that marks out the best cells for repairing bone and cartilage. This will assist the isolation of uniform preparations of these cells for regenerative therapy.
Carbon monoxide exposures after Hurricane Ike - Texas, September 2008.
Authors: N. Hampson, S. Dunn, A. Bronstein, C. Fife, J. Villanacci, D. Zane, M. Forrester, J. Hellsten, R. Beal, C. Beasley, J. Clower, F. Yip, S. Iqbal, C. Martin, C. Cooper, A. Wolkin, M. Podgornik, J. Tokars, S. Benoit
Journal: MMWR Morbidity and Mortality Weekly Report (2009)
Improving NLST criteria for lung cancer screening
Authors: Pablo Sanchez, Juan Pablo De-Torres, David O. Wilson, Joel Weissfeld, Arantzazu Campo, Ana Belen Alcaide, Javier Zulueta
Journal: European Respiratory Journal (2014)

Lung cancer (LC) screening with low dose CT (LDCT) is now recommended by several guidelines. Most of the recommendations rely on the National Lung Screening Trial (NLST). We analyzed the Pamplona Lung Cancer Screening Program (P-ELCAP) and the Pittsburgh Lung Screening Study (PLuSS) in order to evaluate NLST criteria performance.  The P-ELCAP (Spain) and PLuSS (USA), are both LC screening studies that use LDCT ( Chest  2007;132:1932–8,  AJRCCM  2008;178:738–44). Each has different selection criteria, much broader than NLST. We applied NLST entry criteria (55-74y, ≥30pack-y, ≤15y tobacco cessation) and compared diagnostic yields. Incidence density (ID) per 1000 person-years and lung cancer detection rates (LCDR) were calculated for each scenario. The addition of COPD and emphysema as entry criteria was also evaluated.  Almost one third of P-ELCAP (737/2302) participants and 59% of PLuSS (2161/3638) met NLST criteria. Lung cancer ID and LCDR were higher for the NLST subgroups in both cohorts, although several LC cases were missed (40% and 25% of the original cancers, respectively). In comparison to NLST criteria, adding COPD and emphysema to the original entry criteria improved the absolute number of LC diagnoses, the ID, the LCDR, and the number needed to be screened to detect one LC (Table 1 and 2).  LC screening programs based solely in NLST criteria might result in several undetected cases. The presence of COPD and emphysema appear to improve LC detection rates.
Abstract 12704: The Prognosis of Andersen-Tawil Syndrome is Not So Benign as Ever Thought
Authors: Hiromi Kimura, Hideki Itoh, Seiko Ohno, Megumi Fukuyama, Kouichi Kato, Mari Ichikawa, Yusuke Fujii, Takeru Makiyama, Minoru Horie
Journal: Circulation (2014)

Rationale: Andersen-Tawil syndrome (ATS) represents ventricular arrhythmia with abnormal U wave, periodic paralysis, and dysmorphysm, resulting from reduction of I K1 current due to KCNJ2 gene mutation. There are few reports about prognosis of ATS. In 2013, a French group reported that the prognosis of ATS was relatively benign under treatment. However, some our KCNJ2 -positive patients show aborted cardiac arrest in their adult phase. Here, we examined long-term outcome in Japanese KCNJ2 -positive ATS cohort. Methods and Results: In 32 probands with at least one of ATS features, we screened KCNJ2, KCNQ1, KCNH2 , and SCN5A genes. Excluding 2 compound mutations and 1 double mutation cases, we found 14 KCNJ2 mutations in 23 probands (71%). We sent the inquiry sheet to all the attending physicians of probands and collected probands’ symptoms, ECGs, and history of cardiac events. For the average follow-up period of 79 months, four of 23 probands (17%) experienced syncope. Twenty-two of 23 (96%) patients showed ventricular arrhythmias, 10 patients (43%) showed periodic pararysis. We compared 23 probands dividing into two groups; one with syncope (n=4), another without syncope (n=19). There are no significant difference in gender, patient number of ventricular arrhythmia, periodic pararysis, and position of KCNJ2 mutations. ECG findings such as HR (61bpm vs. 80 bpm), QTc (439 msec vs. 404 msec), QUc (668 msec vs. 650 msec), and Tpeak-Upeak interval (233 msec vs. 198 msec) showed no significant difference. The age of diagnosis was significantly higher in syncope group (32 ± 9 year old vs. 16 ± 10 year old, P=0.014). Aborted cardiac arrest (n=2, 50% vs. n=0, P=0.0046), beta blocker use (n=4, 100% vs. n=7, 37%, P=0.011) and ICD implantation (n=2, 50% vs. n=0, P=0.0046) were significantly higher in syncope group. Conclusion: We need to watch attentively KCNJ2 positive probands even after childhood.
From immunogenetic polymorphism to functional antitumor lymphocyte mitochondrial dynamics
Authors: Roman Uzhachenko, Menaka Thounaojam, Anil Shanker
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts The major histocompatibility complex and the leukocyte receptor complex are the two most polymorphic regions of the immune genome. Individuals with increasingly diverse repertoires of MHC class-I molecules have a greater potential for their natural killer (NK) cells to be more
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.
Authors: Karen A. Gelmon, Frances Boyle, Bella Kaufman, David Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martin, Lee Steven Schwartzberg, Susan Faye Dent, Susan Ellard, Katia Sonia Tonkin, Yasir M. Nagarwala, Kathleen I. Pritchard, Timothy Joseph Whelan, Dora Nomikos, Judy-Anne W. Chapman, Wendy Parulekar
Journal: Journal of Clinical Oncology (2012)

LBA671 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Abstract P146: Diabetes, Prediabetes and Risk of Hospitalization: the Atherosclerosis Risk in Communities (ARIC) Study
Authors: Andrea L Schneider, Hsin Chieh Yeh, Rita R Kalyani, Sherita H Golden, Sally C Stearns, Lisa Wruck, Josef Coresh, Elizabeth Selvin
Journal: Circulation (2015)

Introduction:  Diabetes represents a significant proportion of healthcare costs. The magnitude of risk and types of hospitalizations that occur in persons with prediabetes and diabetes are not well characterized.   Hypothesis:  We hypothesized that persons with prediabetes and diabetes would have higher rates of hospitalization, especially from cardiovascular causes, than those without diabetes, and that, in addition to hyper-/hypoglycemia, infection would represent a substantial burden of hospitalizations in persons with diabetes.   Methods:  Prospective analysis of 13,522 participants in the ARIC Study followed for a median of 20 years (1990-2011) for hospitalizations (primary ICD-9 code defined cause). Self-reported history and clinical cut-points of HbA1c were used to define diabetes status at baseline. Negative binomial models were used to calculate demographic-adjusted rates of hospitalization with tests for interaction by age, sex, and race.   Results:  Mean age was 57 years, 56% were female, 24% were black. Persons with diabetes and HbA1c ≥7% had the highest rates of hospitalization (3.1 times higher than those without diabetes; 1.5 times higher than those with diabetes and HbA1c    Conclusions:  Persons with diabetes and prediabetes are at a high risk of hospitalization, but a significant proportion of hospitalizations were for hyper-/hypoglycemia and infection, which may be preventable with improved glycemic control.
Seasonal and Geographic Patterns in Tanning Using Real-Time Data From Google Trends
Authors: Bez Toosi, Sunil Kalia
Journal: JAMA Dermatology (2015)

Results | Frequencies for the study variables are shown in Table 1, which also shows the results of bivariable logistic regression analyses examining correlates of Internet access.Of the 176 study participants, Internet access was reported by 148 (84.1%) and was associated with being younger, having a higher educational level, and having greater knowledge of the ABCDE signs of melanoma.One hundred nineteen of 174 participants (68.4%) reported being at least moderately interested in an Internetdelivered behavioral intervention (Table 2).As shown in the bivariable logistic regression analyses in Table 2, individuals who were at least moderately interested in an Internetdelivered behavioral intervention were more likely to be younger, have greater knowledge of the ABCDE signs of melanoma, and be more comfortable using the Internet.Discussion | As expected, most of the study participants had access to the Internet.Internet access was associated with being younger and having a higher level of education.Most of the participants were at least moderately interested in an Internetdelivered behavioral intervention.Older participants, individuals with lower knowledge of the ABCDE signs of melanoma, and those who reported less comfort using the Internet exhibited less receptivity to an Internet-delivered intervention.These results suggest that individuals who may not perform SSEs effectively (ie, those with low knowledge of the ABCDE signs of melanoma) may be less receptive to an Internet-delivered intervention.Developers of e-health interventions should consider and address such challenges.Formative research should consider ways to improve the appeal of Internet-delivered and/or non-Internetdelivered interventions to those groups who were less receptive or who lacked Internet access.Among participants with Internet access, receptivity to an Internet-delivered behavioral intervention did not differ significantly based on previous online seeking of melanoma information.Thus, e-health interventions may still appeal to patients with melanoma who have not sought melanoma information online in the past.This work highlights potential limitations of the reach of e-health interventions and identifies factors associated with the receptivity of patients with melanoma to such interventions.Limitations of this study include the crosssectional nature of the data and inclusion of patients from a single institution.Little research has formally evaluated e-health interventions that promote SSEs and sun protection behaviors among patients with melanoma or individuals at increased risk for melanoma, 3,6 and future research is warranted to develop and test relevant theory-based interventions.
A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor
Authors: Y. Fujiwara, N. Yamamoto, K. Yamada, Y. Yamada, T. Shimoyama, F. Koizmi, K. Nishio, T. Otsuki, S. R. Frankel, T. Tamura
Journal: Journal of Clinical Oncology (2007)

14015 Background: Vorinostat (Zolinza™), a potent inhibitor of histone deacetylase (HDAC), induces tumor growth inhibition, differentiation, and apoptosis in vitro. Increasing evidence has revealed clinical activity of vorinostat in patients (pts) with various types of cancer including cutaneous T-cell lymphoma. Methods: Japanese pts with solid tumor who failed standard therapy were enrolled in a single institution, National Cancer Center hospital, Phase I study. Pts were dosed with vorinostat BID for 14 consecutive days followed by 7 day-rest starting at 100 mg and escalated by 100 mg BID until MTD was established. Subsequently single daily dosing was tested at 400 and 500 mg. PK was measured at total of 41 timepoints. Response was also evaluated according to the international workshop criteria. Results: MTD was established as 200 mg BID and 500 mg QD for 14 consecutive days followed by a 7 day-rest. All 18 enrolled pts were assessed for safety and PK. Median age was 58 yrs [25–72]. Ten of 18 pts had lung cancer. Two of 6 pts receiving 200 mg BID experienced DLTs: Grade 4 thrombocytopenia, and Grade 4 thrombocytopenia and Grade 3 anorexia. None of 3 pts receiving 400 mg QD experienced DLT. One of 6 pts receiving 500 mg QD experienced Grade 3 anorexia and fatigue. AUC of vorinostat increased generally proportional to dose in the range of 100–500 mg. PK was not greatly affected by multiple doses. Intact drug was hardly excreted in urine (&lt;1% of dose). PK profile is similar to that established in US pts. As of Dec 2006, 1 pt with invasive thymoma received 200 mg BID for 1 yr. Nine pts achieved SD as best response. Conclusions: This study demonstrates the safety of vorinostat 200 mg BID and 500 mg QD for 14 consecutive days followed by 7 day-rest. These would be the RD for Phase II studies on this schedule. No significant financial relationships to disclose.
Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis
Authors: Marie Tauber, Stefana Balica, Chiung-Yueh Hsu, Catherine Jean-Decoster, Christophe Lauze, Daniel Redoules, Cécile Viodé, Anne-Marie Schmitt, Guy Serre, Michel Simon, Carle F. Paul
Journal: Journal of Allergy and Clinical Immunology (2015)
Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes.
Authors: Yair Lotan, Jeffrey A. Cadeddu, J. Jack Lee, Claus G. Roehrborn, Scott M. Lippman
Journal: Cancer Research (2005)

483   The Prostate Cancer Prevention Trial (PCPT) found that finasteride produced a 25% relative risk reduction in the period prevalence of prostate cancer versus placebo. A greater proportion of tumors of Gleason scores ≥ 7, however, were found in the finasteride group (37% vs. 22%). The present study assessed the estimated effect of finasteride prevention of prostate cancer (as measured in the PCPT) on overall survival. We created a decision tree model for comparing survival outcomes of finasteride-treated men with survival outcomes of men not treated with finasteride. All published predictive data integrated into this model came from men meeting the PCPT entry criteria. We abstracted the probability of survival for patients with clinically localized prostate cancer from studies with long-term survival outcomes. We evaluated the effects of different prostate-cancer detection rates (eg, associated with PSA level) in the study population. We also determined survival outcomes in scenarios with and without differences in Gleason score distribution. Based on published prostate cancer survival probabilities and on the Gleason-score distribution and prostate-cancer prevalence rates in the PCPT, a finasteride-treated population gains 1.7 months of added survival in 15-year cause-specific survival. If the Gleason score distributions of prostate cancers that develop in the finasteride and control groups are assumed to be equivalent, then the finasteride group gains up to a 3-month survival advantage whether the cancers are treated either conservatively or surgically. An analysis including PCPT cancers detected by for-cause biopsies indicated that finasteride treatment conferred a 0.35-months survival advantage but this advantage increased to 1.7 months when assuming a 30% rate of biopsy-detected cancer in the placebo group. Model variability analyses support several of the finasteride-associated survival benefits (eg, the uniformly beneficial results based on the assumption that finasteride does not alter Gleason-score distribution) but question certain other finasteride survival benefits (eg, in 15-year recurrence-free survivals). The benefit imparted by finasteride chemoprevention on life expectancy based on the PCPT results is small primarily because prostate cancer develops in only a minority of men treated or not with finasteride. A finasteride-treated population in which prostate cancer patients are treated by radical prostatectomy has a 15-year cause-specific survival advantage of 1.7 months and a 10-year metastases-free survival advantage ranging from 1-2 months. These advantages are considerably higher when assuming that finasteride does not alter Gleason score distribution. Cervical cancer screening, routine immunizations, tamoxifen to prevent breast cancer, and other standard preventive strategies result in similar survival benefits (
Abstract #5121: Sensitizaton of ovarian cancer cell lines to death receptor ligands by the flexible heteroarotinoid (Flex-Het), SHetA2
Authors: Shylet Chengedza, Doris Benbrook
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

The lead Flexible Heteroarotinoid (Flex-Het) compound, SHetA2, induces apoptosis in cancer cells by altering the balance between pro- and anti-apoptotic Bcl-2 proteins in cancer cells with very little effect on normal cells. In addition, SHetA2 regulates differentiation through upregulation of E-cadherin, cell cycle progression through inhibition of Cyclin D1, angiogenesis through inhibition of thymidine phosphorylase and vascular endothelial growth factor expression and carcinogenesis through counteraction of carcinogen-induced alterations in gene expression patterns. Nuclear Factor Kappa B (NF-\#954;B) regulates expressions of these genes in an opposite manner as SHetA2. Therefore, it was hypothesized that SHetA2 regulates apoptosis through inhibition of NF-\#954;B signaling. The effects of SHetA2 on NF-\#954;B signaling and cell death induced by death receptor ligands, Tumor Necrosis Factor Alpha (TNF\#945;) and TNF\#945; Related Apoptosis-Inducing Ligand (TRAIL) were evaluated in ovarian cancer cell lines. SHetA2 inhibited basal, TNF\#945;- and hydrogen peroxide induced NF-\#954;B activity, but did not alter DNA binding or the makeup of the individual components in the NF-\#954;B DNA binding complex. This inhibition was associated with: decreased phosphorylation of I\#954;B\#945;; decreased activity of IKK enzyme; and induction of apoptosis. Ovarian cancer cell lines were resistant to the death receptor ligands, but combined treatment of SHetA2 with TNF\#945; and TRAIL resulted in synergistic apoptosis through simultaneous induction of the intrinsic and extrinsic apoptosis pathways. SHetA2 induced expression of Death Receptor 5 (DR5), the cognate receptor for TRAIL thereby priming ovarian cancer cells for sensitization to TRAIL induced apoptosis. DR5 is inhibited by NF-\#954;B. In summary, inhibition of the NF-\#954;B survival pathway by SHetA2 relieves the cellular constraints that prevent TNF\#945; - and TRAIL-induced apoptosis in ovarian cancer cells. Potentiation of apoptosis by combination treatment of SHetA2 and death receptor ligands in death receptor ligands resistant cancer cells provides a rationale for use of these combination treatments in future preclinical and clinical studies.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5121.
Smart hydrogel beads with potential therapeutic target in Caco-2 colon cancer cells
Authors: Alessandro F. Martins, Johny P. Monteiro, Suelen P. Facchi, Letícia C. Bonkovoski, Cleiser T.P. Silva, Adriana P. Gerola, Samara R. Nocchi, Celso V. Nakamura, Emerson M. Girotto, Adley F. Rubira, Edvani C. Muniz
Journal: Journal of Controlled Release (2015)
Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions
Authors: S Volkert, T Haferlach, J Holzwarth, M Zenger, W Kern, M Staller, Y Nagata, K Yoshida, S Ogawa, S Schnittger, C Haferlach
Journal: Leukemia (2015)
The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas.
Authors: P Colombat, N C Gorin, M P Lemonnier, C Binet, J P Laporte, L Douay, I Desbois, M Lopez, J P Lamagnere, A Najman
Journal: Journal of Clinical Oncology (1990)

Forty-six patients with non-Hodgkin's lymphoma (NHL) were treated with autologous bone marrow transplantation (ABMT) in two different institutions. All patients were pretreated with conventional chemotherapy. Three different conditioning regimens were used, and 20 patients underwent bone marrow purging. Twelve patients were treated in first complete remission (CR); eight are in unmaintained CR 8 to 104 months after ABMT. Five patients were grafted in first partial remission (PR) after conventional therapy; all achieved CR, and all remain in prolonged CR (first CR for four patients, second CR for one patient). Of 21 patients with chemosensitive relapses, 13 patients are in prolonged unmaintained CR 8 to 94 months after ABMT. Eight patients with resistant disease remained uncured by ABMT; all eight died, six from progressive illness and two from toxicity. The current 3-year disease-free probability is 60% for all patients, 0% for refractory disease; 82% for first PR or CR, and 60% for sensitive relapses (SRs). These results confirm the efficacy of ABMT in the treatment of chemosensitive NHL with bad prognosis.